ITI Pharma and Healthcare Fund Direct-Growth
Equity: Sectoral-Pharma - Growth (Open ended) Factsheet
SEBI Riskometer: Very HighCategory: Equity: Sectoral-PharmaBenchmark: NIFTY Healthcare Total Return Index.
NAV: ₹19.39+0.01%
16 Jul 2026
Holdings Analysis
Equity, debt and cash allocation snapshot with market cap distribution for ITI Pharma and Healthcare Fund Direct-Growth.
Market Cap Distribution
Large Cap (36.7%)
Mid Cap (43.5%)
Small Cap (19.8%)
Historical Asset Allocation
| Asset | 30 Jun 2026 | 31 May 2026 | 30 Apr 2026 | 31 Mar 2026 | 28 Feb 2026 | 31 Jan 2026 |
|---|---|---|---|---|---|---|
| Equity | 96.78% | 98.01% | 98.25% | 99.18% | 98.22% | 98.24% |
| Debt | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Others (incl. cash) | 3.22% | 1.99% | 1.75% | 0.82% | 1.78% | 1.76% |
| Commodities | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Real Estate | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Portfolio Snapshot
No. of Securities
38
P/E Ratio
45.24
P/B Ratio
5.78
Top Holding %
13.34%
Top 5 Holdings %
37.20%
Top 10 Holdings %
58.16%
AUM
₹252 Cr
Expense Ratio
0.98%
Since Inception
15.18%
Max Drawdown
-0.18%
Alpha
-2.51%
Sharpe Ratio
0.91
Top Portfolio Holdings by Weight
Latest portfolio holdings sorted by allocation weight. Includes instrument name, sector, number of shares, market value (₹ Cr) and percentage of net assets. Switch dates or categories using the controls below.
| Instrument | Sector | No. of Shares | Value (Rs. Cr) | Weight | Change |
|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Ltd. | Healthcare | 1,80,398 | 33.6 | 13.34% | -0.91%↓ |
| Divis Laboratories Ltd. | Healthcare | 25,990 | 17.1 | 6.79% | -1.64%↓ |
| Apollo Hospitals Enterprise Ltd. | Healthcare | 18,032 | 15.66 | 6.22% | 0.02%↑ |
| Dr. Reddys Laboratories Ltd. | Healthcare | 1,00,879 | 13.69 | 5.44% | 1.46%↑ |
| Max Healthcare Institute Ltd. | Healthcare | 1,20,721 | 13.63 | 5.41% | 0.51%↑ |
| Cipla Ltd. | Healthcare | 79,036 | 11.58 | 4.60% | 1.18%↑ |
| Torrent Pharmaceuticals Ltd. | Healthcare | 24,834 | 11.47 | 4.56% | -0.34%↓ |
| Laurus Labs Ltd. | Healthcare | 73,055 | 11.09 | 4.40% | -0.66%↓ |
| Aurobindo Pharma Ltd. | Healthcare | 65,463 | 10.33 | 4.10% | -0.18%↓ |
| Lupin Ltd. | Healthcare | 34,373 | 8.31 | 3.30% | -0.23%↓ |
| Neuland Laboratories Ltd. | Healthcare | 4,185 | 7.78 | 3.09% | 0.09%↑ |
| Fortis Healthcare Ltd. | Healthcare | 77,471 | 7.41 | 2.94% | -0.08%↓ |
| Cohance Lifesciences Ltd. | Healthcare | 1,59,791 | 7.29 | 2.89% | 0.24%↑ |
| Mankind Pharma Ltd. | Healthcare | 28,118 | 7.16 | 2.84% | 0.89%↑ |
| Alkem Laboratories Ltd. | Healthcare | 12,453 | 6.94 | 2.75% | -0.13%↓ |
| Global Health Ltd. | Healthcare | 38,559 | 5.07 | 2.01% | - |
| Abbott India Ltd. | Healthcare | 1,800 | 4.58 | 1.82% | -0.21%↓ |
| Aster DM Healthcare Ltd. | Healthcare | 49,392 | 3.87 | 1.54% | -0.25%↓ |
| Ipca Laboratories Ltd. | Healthcare | 22,488 | 3.83 | 1.52% | 0.08%↑ |
| Sai Life Sciences Ltd. | Healthcare | 26,441 | 3.26 | 1.30% | -0.33%↓ |
1 / 2
Sector-wise Portfolio Allocation
Equity exposure by sector as a percentage of total net assets, tracked across recent portfolio dates. Identifies concentration risk and sector rotation trends in the fund's holdings.
| Sector | 30 Jun 2026 | 31 May 2026 | 30 Apr 2026 | 31 Mar 2026 | 28 Feb 2026 | 31 Jan 2026 |
|---|---|---|---|---|---|---|
| Healthcare | 92.31% | 91.57% | 92.15% | 92.34% | 91.49% | 93.39% |
| Chemicals | 1.25% | 2.42% | 2.65% | 3.66% | 3.46% | 2.54% |
| Materials | 1.22% | 1.47% | 1.29% | 1.11% | 0.99% | - |
| Metals & Mining | 0.95% | 0.81% | - | - | - | - |
| Capital Goods | 0.54% | - | 0.91% | 0.82% | 0.92% | 0.90% |
| Financial | 0.51% | 0.51% | - | - | - | - |
| Insurance | - | 1.22% | 1.26% | 1.25% | 1.36% | 1.41% |
Equity Insights
A detailed look at the equity holdings of this scheme — aggregated scores on value, momentum, quality parameters along with diversification and performance analysis.
Style Analysis
Value score
24.6 / 100
Weighted average Value score is 24.6. This indicates that portfolio is relatively overvalued using composite of value measures.
Price Momentum score
76.0 / 100
Weighted average Price Momentum score is 76.0. This indicates that portfolio has high momentum using composite of momentum measures.
Quality score
83.2 / 100
Weighted average Quality score is 83.2. This indicates that portfolio has high quality using composite of quality measures.
QVM score
70.1 / 100
Weighted average QVM score is 70.1. This indicates that portfolio has average QVM score and hence a neutral stance is warranted.
Red Flags
Frequently Asked Questions
What are the top holdings of ITI Pharma and Healthcare Fund Direct-Growth?
The top holdings of ITI Pharma and Healthcare Fund Direct-Growth as of 30 Jun 2026 are Sun Pharmaceutical Industries Ltd. (13.34%), Divis Laboratories Ltd. (6.79%), Apollo Hospitals Enterprise Ltd. (6.22%), Dr. Reddys Laboratories Ltd. (5.44%), Max Healthcare Institute Ltd. (5.41%). These top 5 stocks together account for 37.20% of the total portfolio. You can view the complete holdings breakdown above.
How many stocks does ITI Pharma and Healthcare Fund Direct-Growth hold in its portfolio?
ITI Pharma and Healthcare Fund Direct-Growth holds 38 stocks in its portfolio as of 30 Jun 2026. The fund's portfolio size reflects the fund manager's investment approach, a more concentrated portfolio indicates higher conviction bets, while a larger number of holdings suggests a more diversified strategy.
What is the sector allocation of ITI Pharma and Healthcare Fund Direct-Growth?
As of 30 Jun 2026, ITI Pharma and Healthcare Fund Direct-Growth's top sector allocations are Healthcare (92.31%), Chemicals (1.25%), Materials (1.22%). You can find detailed sector allocation above.
What is the equity and debt allocation of ITI Pharma and Healthcare Fund Direct-Growth?
As of 30 Jun 2026, ITI Pharma and Healthcare Fund Direct-Growth has 96.78% allocated to equity, and 0.00% to debt. You can also check the historical trends above.
What is the market cap allocation of ITI Pharma and Healthcare Fund Direct-Growth?
As of 30 Jun 2026, ITI Pharma and Healthcare Fund Direct-Growth's market cap allocation is 36.69% in large caps, 43.49% in mid caps, and 19.82% in small caps.
What is the PE ratio of ITI Pharma and Healthcare Fund Direct-Growth's portfolio?
The portfolio PE ratio of ITI Pharma and Healthcare Fund Direct-Growth is 45.24 as of 30 Jun 2026. The portfolio PE ratio tells you how expensive or cheap the fund's holdings are relative to their earnings.
What is the credit quality of ITI Pharma and Healthcare Fund Direct-Growth?
A credit rating breakdown is not available for ITI Pharma and Healthcare Fund Direct-Growth — its non-equity allocation was 0.00% as of the latest disclosure. This is common when a fund's non-equity holdings are mostly cash or short-term money market instruments, which aren't assigned a credit rating the way bonds are.
When is the latest portfolio disclosure for ITI Pharma and Healthcare Fund Direct-Growth?
The latest portfolio disclosure for ITI Pharma and Healthcare Fund Direct-Growth is as of 30 Jun 2026. SEBI requires all mutual funds to disclose their complete portfolio holdings on a monthly basis, typically within 10 days of the end of each month.